Immunotherapy – stimulating the body’s defenses to recognize and destroy disease-causing cells and proteins – was dubbed the “breakthrough of the year” in 2013 by Science magazine. Dana-Farber researchers have contributed many important discoveries over the years about how the immune system works. Now, they are building on these insights to develop immunotherapy against tumors – known as immuno-oncology. In 2005 Dana-Farber established the Cancer Vaccine Center (CVC) under the leadership of Ellis Reinherz, MD, Jerome Ritz, MD, and Glenn Dranoff, MD. The mission of the CVC is to translate the promising insights from basic immunology into therapeutics that benefit …
When cancer develops in someone with other diseases, it can be more serious, according to a recent annual report from several national cancer organizations. “Cancer does not occur in isolation,” says Lawrence Shulman, MD, in commenting on the report. “It occurs in a human being, who may have other medical problems.”
By Richard Saltus Though quite curable when diagnosed early, kidney cancer in advanced stages can become a stubborn disease. However, the outlook for patients with metastatic kidney cancer has brightened in the past several years. Oncologists have added to their arsenal a number of designer drugs that attack molecular targets – genetic abnormalities that drive tumors – with high specificity.
For about 70 years, the standard treatment for patients with advanced prostate cancer was drugs that blocked male hormones feeding the tumor. If that stopped working and the disease progressed, oncologists turned to chemotherapy to kill the cancer cells. This timetable is about to change. Results of a clinical trial led by a Dana-Farber researcher revealed that such patients lived longer if started on both a hormone blocker and a chemotherapy drug at the same time. The government-sponsored trial found that 69 percent of men receiving both treatments were alive at three years, compared with 52.5 percent of men who …
Dana-Farber Cancer Institute’s Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH recently partnered with CancerConnect to answer questions about breast cancer therapies. Burstein and Mayer are breast oncologists in the Center for Breast Oncology at Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Q: What medications are helpful for depression after breast cancer treatment and while taking tamoxifen?
Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.
Experts with the U.S. Preventive Services Task Force (USPSTF) have recommended that current smokers and former-smokers who recently quit should undergo an annual low-dose CT scan to screen for lung cancer.
As 2013 comes to a close, we’re looking back at some of our favorite Insight posts from the last year. From inspiring patient stories to important research, here is our top 10 list: